Concord Drugs Ltd Financials

Concord Drugs Ltd Financial Statement

Concord Drugs Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Dec 2024	Sep 2024	Jun 2024
Revenue	10.77	11.85	6.35
Operating Expense	9.46	11.05	5.62
Net Profit	0.22	0.05	0.01
Net Profit Margin	2.04	0.42	0.16
Earning Per Share	0.22	0.05	0.01
EBIDTA	1.16	0.81	0.74
Effective Tax Rate	10.69	3.75	2.74

Particulars	Dec 2024
Revenue	10.77
Operating Expense	9.46
Net Profit	0.22
Net Profit Margin	2.04
Earning Per Share	0.22
EBIDTA	1.16
Effective Tax Rate	10.69

Concord Drugs Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	43.26	51.31	58.96
Operating Expenses Annual	39.58	46.97	53.36
Operating Profit Annual	3.69	4.35	5.69
Interest Annual	1.59	1.62	1.68
Depreciation	1.54	1.60	1.76
Net Profit Annual	0.42	0.89	1.59
Tax Annual	0.14	0.23	0.65

Particulars	Mar 2024
Total Revenue Annual	43.26
Operating Expenses Annual	39.58
Operating Profit Annual	3.69
Interest Annual	1.59
Depreciation	1.54
Net Profit Annual	0.42
Tax Annual	0.14

Concord Drugs Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	0.08	0.04	0.04
Cash Flow from Operations	1.96	2.24	0.77
Cash Flow from Investing	-1.21	-2.27	-2.44
Cash Flow from Financing	-0.69	0.05	1.68
Cash Flow at the End	0.14	0.08	0.04

Particulars	Mar 2024
Cash Flow at the Beginning	0.08
Cash Flow from Operations	1.96
Cash Flow from Investing	-1.21
Cash Flow from Financing	-0.69
Cash Flow at the End	0.14

Concord Drugs Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	8.53	8.48	9.65
PBIT Margin (%)	4.97	5.36	6.67
PBT Margin (%)	1.85	2.07	2.72
Net PROFIT Margin (%)	0.97	1.73	2.70
Return On Networth / Equity (%)	1.28	2.96	5.77
Return On Networth /Employed (%)	4.25	5.67	8.80
Return On Assets (%)	0.83	1.84	3.56
Total Debt / Equity (X)	0.47	0.53	0.53
Asset Turnover Ratio (%)	0.86	1.06	1.32

Particulars	Mar 2024
PBDIT Margin (%)	8.53
PBIT Margin (%)	4.97
PBT Margin (%)	1.85
Net PROFIT Margin (%)	0.97
Return On Networth / Equity (%)	1.28
Return On Networth /Employed (%)	4.25
Return On Assets (%)	0.83
Total Debt / Equity (X)	0.47
Asset Turnover Ratio (%)	0.86

Concord Drugs Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	10.99	12.22	13.33
Total Current Assets Annual	41.38	41.40	41.89
Non Current Assets Annual	14.92	15.23	14.55
Total Shareholders Funds Annual	33.82	31.70	28.36
Total Assets Annual	56.30	56.63	56.45

Particulars	Mar 2024
Fixed Assets Annual	10.99
Total Current Assets Annual	41.38
Non Current Assets Annual	14.92
Total Shareholders Funds Annual	33.82
Total Assets Annual	56.30

Concord Drugs Ltd Earning Calls

EPS (INR)

Expected

0.23

Reported

0.23

Surprise

0.00%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dividend Pages

PE Ratio

Get Your FAQs Right

As of Jan 15, 2025, Concord Drugs Ltd has a market capitalization of 35.17 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Concord Drugs Ltd is debt-free with a debt-to-equity ratio of 0.41.

In FY 2024 , Concord Drugs Ltd recorded a total revenue of approximately 43.26 Cr marking a significant milestone in the company's financial performance.

Concord Drugs Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and -0.2% annually, respectively..

Concord Drugs Ltd's current PE ratio is 83.74.

Concord Drugs Ltd's ROCE averaged 6.4% from the FY ending March 2022 to 2024, with a median of 5.9%. It peaked at 8.9% in March 2022, reflecting strong capital efficiency over the period..

Concord Drugs Ltd's latest EBIT is Rs. 2.15 Cr, surpassing the average EBIT of Rs. 2.94 Cr over the 5 years..